Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 11;1(1):18-22.
doi: 10.1515/mr-2021-0031. eCollection 2021 Oct.

A novel function of CREG in metabolic disorders

Yang Li  1 , Xiaoxiang Tian  1 , Quanyu Zhang  1 , Chenghui Yan  1 , Yaling Han  1
Affiliations
Review

A novel function of CREG in metabolic disorders

Yang Li et al. Med Rev (2021). .

Abstract

Metabolic disorders are public health problems that require prevention and new efficient drugs for treatment. Cellular repressor of E1A-stimulated genes (CREG) is ubiquitously expressed in mature tissues and cells in mammals and plays a critical role in keeping cells or tissues in a mature, homeostatic state. Recently, CREG turns to be an important mediator in the development of metabolic disorders. Here in this review, we briefly discuss the structure and molecular regulation of CREG along with the therapeutic strategy to combat the metabolic disorders.

Keywords: CREG; NAFLD; insulin resistance; metabolic disorders; obesity; skeletal muscle energy metabolism.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Authors state no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Su ZQ, Guo YR, Huang XF, Feng B, Tang LP, Zheng GJ, et al. Phytochemicals: targeting mitophagy to treat metabolic disorders. Front Cell Dev Biol. 2021;9:686820. doi: 10.3389/fcell.2021.686820. - DOI - PMC - PubMed
    1. Garg R, Kumariya S, Katekar R, Verma S, Goand UK, Gayen JR. JNK signaling pathway in metabolic disorders: an emerging therapeutic target. Eur J Pharmacol. 2021;901:174079. doi: 10.1016/j.ejphar.2021.174079. - DOI - PubMed
    1. Veal E, Eisenstein M, Tseng ZH, Gill G. A cellular repressor of E1A-stimulated genes that inhibits activation by E2F. Mol Cell Biol. 1998;18:5032–41. doi: 10.1128/mcb.18.9.5032. - DOI - PMC - PubMed
    1. Veal E, Groisman R, Eisenstein M, Gill G. The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells. Oncogene. 2000;19:2120–8. doi: 10.1038/sj.onc.1203529. - DOI - PubMed
    1. Di Bacco A, Gill G. The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor. Oncogene. 2003;22:5436–45. doi: 10.1038/sj.onc.1206670. - DOI - PubMed

LinkOut - more resources